Clinical Trial Update: A First Human Dose Study to Investigate Safety and Tolerability of LY2979165 in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 first-in-human study of LY2979165 in healthy volunteers has completed, assessing safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• LY2979165

Snippet

Sponsor: Eli Lilly and Company | Conditions: Bipolar Disorder | Phase 1 | Status: COMPLETED